Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2024 | Promising therapies under investigation in AL amyloidosis: IMiDs & bispecific antibodies

Patrick Hagen • 28 May 2024
ISA 2024
Amyloidosis Rare Diseases Antibodies Daratumumab Teclistamab

Patrick Hagen, MD, Loyola University Medical Center, Chicago, IL, gives an overview of current therapies under investigation for the treatment of light chain (AL) amyloidosis. Drug discovery across various plasma cell disorders has provided new treatments for AL amyloidosis, including novel immunomodulatory drugs (IMiDs) and bispecific antibodies. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Speakers Bureau Sanofi

More from Patrick Hagen

Timing and patient selection for stem cell transplantation in systemic AL amyloidosis
2:11
Timing and patient selection for stem cell transplantation in systemic AL amyloidosis
Patrick Hagen • 28 May 2024

Related Videos

How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
1:40
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
Naveen Pemmaraju • 30 May 2026
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
2:20
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
Naveen Pemmaraju • 29 May 2026
The importance of alloSCT in improving outcomes for patients with BPDCN
1:40
The importance of alloSCT in improving outcomes for patients with BPDCN
Naveen Pemmaraju • 29 May 2026
The content of VJHemOnc is intended for healthcare professionals